Facing a significant stock decline and a challenging Medicare Advantage outlook, UnitedHealth Group announces leadership changes and a 'Back to Basics' operational reset, aiming to stabilize its core business amid shifting market dynamics.
Google's parent company unveils an AI-powered tool for generating interactive 3D worlds, signaling a strategic push into the core technology of game development and virtual experiences, with potential ripple effects across content creation and cloud infrastructure.
Terex Corporation's shares have experienced notable swings, declining over 4% last week but gaining nearly 7% in the past month. A fresh look at its valuation through discounted cash flow and peer comparisons suggests the stock may be trading at a significant discount to its intrinsic value.
Initial unemployment filings in Washington fell slightly last week, even as national figures held steady and other states experienced sharp swings, according to the latest federal data.
Applied Optoelectronics (AAOI) shares have experienced significant volatility following a major 800G transceiver order and strategic expansion into AI-focused products. With the stock trading above analyst targets after a strong multi-year run, investors are weighing future growth prospects against current valuation concerns.
Dolby Laboratories (DLB) shares, closing at $64.19, present a complex picture for investors. While short-term momentum shows signs of improvement, longer-term returns have lagged, sparking debate over whether the audio technology pioneer is fundamentally undervalued or facing structural headwinds.
As global travel surges past pre-pandemic records, the influx of visitors is straining infrastructure and reshaping communities worldwide. From European protests to quiet American suburbs, the quest for authentic experiences is colliding with local life, fueling a housing crisis and raising a critical question: can cities belong to both residents and tourists?
Solid-state battery developer QuantumScape appoints former NVIDIA CFO Geoffrey Ribar to its board, signaling a strategic shift towards manufacturing discipline and capital allocation as it transitions from R&D to pilot production.
Private equity giant Thoma Bravo is exploring a sale of Imprivata, a key player in healthcare digital identity software, in a deal that could value the company at up to $7 billion, sources tell Reuters.
In a dramatic market reversal, Bitcoin demonstrates resilience while gold and silver experience historic single-day declines, triggered by shifting interest rate expectations following a surprise Federal Reserve chair nomination.
After the COVID-19 windfall subsided, Pfizer CEO Albert Bourla is steering the pharmaceutical giant into a high-stakes, $23 billion pivot to cancer research. Facing a looming patent cliff and plummeting vaccine revenue, Bourla is betting on scientific innovation to secure the company's future—and redefine cancer treatment.
While stocks priced between $10 and $50 can offer an appealing mix of accessibility and relative maturity, savvy investors know the sticker price is just the beginning. We examine one company in this range that appears poised for growth and two where the fundamentals warrant a closer, more cautious look.
Market volatility presents both risk and opportunity. We analyze two fundamentally sound yet turbulent stocks that may reward the patient, and flag one whose wild swings are best left to speculators.
Lyft's stock has experienced significant volatility, with recent gains failing to offset broader declines. As the company pushes its autonomous driving and European expansion narrative, investors are left weighing its premium valuation against a challenging competitive landscape and uncertain path to sustained profitability.
Reed Jobs, son of the late Apple co-founder Steve Jobs, has secured over $200 million for Yosemite, a venture fund dedicated to pioneering cancer treatments. Backed by major institutions, the fund seeks to transform cancer from a fatal diagnosis to a chronic, manageable disease within a generation.
DexCom Inc. (DXCM) has released preliminary Q4 figures that exceeded expectations and provided robust long-term guidance, reinforcing its position as a favored pick among analysts and hedge funds in the medical devices sector.
Gold and silver prices experienced a dramatic sell-off following President Trump's surprise nomination of former Fed governor Kevin Warsh to chair the Federal Reserve, sparking intense debate over future monetary policy direction.
French biopharma firm Inventiva (ENXTPA:IVA) has delivered a stunning 126% total return to shareholders over the past year, sharply contrasting with losses over a three-year horizon. As the stock experiences short-term pullbacks, analysts debate whether its current €5.23 price reflects future promise or present hype, with a key drug candidate hanging in the balance.
President Trump's nomination of Kevin Warsh to lead the Federal Reserve has sent ripples through cryptocurrency markets, as traders assess the implications of a governor with direct crypto investment experience and a hawkish monetary policy reputation.
Eli Lilly bolsters its long-term growth strategy through two new R&D partnerships and a key regulatory milestone for an ovarian cancer drug, signaling a strategic push beyond its blockbuster diabetes and obesity treatments.
